Sign in
DC

DANAHER CORP /DE/ (DHR)·Q3 2025 Earnings Summary

Executive Summary

  • Q3 2025 delivered a clean beat: revenue $6.05B vs S&P Global consensus $6.00B and adjusted EPS $1.89 vs $1.72; strength came from bioprocessing consumables and earlier-than-usual respiratory purchases at Cepheid . EPS and revenue beats are significant catalysts; management also announced a new buyback authorization (up to 35M shares) after repurchasing ~$2B (10M shares) in Q3, supporting per-share growth .
  • Gross margin was 58.2%, and adjusted operating margin rose to 27.9% (up ~40 bps YoY), reflecting volume leverage and cost discipline despite productivity investments . Free cash flow rose to $1.37B, ahead of expectations, reinforcing cash conversion quality .
  • Guidance maintained: FY25 adjusted EPS $7.70–$7.80; Q4 assumptions include low-single-digit core growth, adjusted operating margin ~27%, and tax rate ~17% . Segment outlook for Q4: Biotechnology ~+5%, Life Sciences low-single-digit decline, Diagnostics flat .
  • 2026 framework: core growth 3–6% and >100 bps adjusted operating margin expansion, aided by ~$250M net savings ($0.30 EPS tailwind); respiratory revenue at Cepheid expected ~$1.7B in 2026, consistent with 2025, anchoring stability .

What Went Well and What Went Wrong

  • What Went Well

    • “DBS-driven execution paired with continued momentum in our bioprocessing business and better-than-anticipated respiratory revenue at Cepheid enabled us to exceed our revenue, earnings and cash flow expectations.” — CEO Rainer M. Blair .
    • Biotechnology core revenue +6.5% led by double-digit consumables demand in commercialized therapies; strong positioning across biologics workflow highlighted by Cytiva launches and capacity investments .
    • Cepheid non-respiratory menu grew mid/high-teens with ~20% sexual health growth; installed base expansion across IDNs supports durable pull-through .

  • What Went Wrong

    • Life Sciences core declined 1% on lower demand for plasmids/mRNA from two large customers and continued academic/government funding pressure; equipment remained soft .
    • China diagnostics headwinds from VBP/reimbursement persisted; management sized a modest 2026 headwind ($75–$100M) despite lapping impacts in Q4 2025 .
    • Bioprocessing equipment orders remained delayed amid policy uncertainty (tariffs/MFN); book-to-bill around 1 with lumpiness, pushing a cautious stance on equipment through year-end .

Financial Results

MetricQ3 2024Q2 2025Q3 2025S&P Global Consensus (Q3 2025)
Revenue ($USD Billions)$5.80 $5.94 $6.05 $6.00*
Diluted EPS (GAAP, $)$1.12 $0.77 $1.27 —
Adjusted Diluted EPS (Non-GAAP, $)$1.71 $1.80 $1.89 $1.72 (Primary EPS)*
ProfitabilityQ1 2025Q2 2025Q3 2025
Gross Margin %61.2% 59.3% 58.2%
Adjusted Operating Margin %29.6% 27.3% 27.9%
Cash Flow KPIs ($USD Billions)Q1 2025Q2 2025Q3 2025
Operating Cash Flow$1.30 $1.34 $1.66
Free Cash Flow$1.06 $1.09 $1.37
Capex$0.245 $0.248 $0.292
Segment Core Sales Growth (YoY, Q3 2025)Growth %
Total Company (Core)+3.0%
Biotechnology+6.5%
Life Sciences-1.0%
Diagnostics+3.5%
Total GAAP Sales Growth+4.5%

Notes: Values with asterisk retrieved from S&P Global.
S&P Global Estimate Table

MetricQ3 2025 ConsensusQ3 2025 Actual
Primary EPS Consensus Mean ($)1.72163*1.89
Revenue Consensus Mean ($)5,997,749,920*6,053,000,000
# EPS Estimates20.0*—
# Revenue Estimates19.0*—

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Adjusted Diluted EPS (Non-GAAP)FY 2025$7.70–$7.80 $7.70–$7.80 Maintained
Core Revenue Growth (Non-GAAP)FY 2025~3% Low-single digits Maintained/clarified
Adjusted Operating MarginQ4 2025—~27% New Q4 detail
Core Sales Growth by SegmentQ4 2025—Biotech ~+5%; Life Sciences low-single-digit decline; Diagnostics flat New Q4 detail
Effective Tax RateQ4 2025—~17% New
Corporate Expense (Other segment OP)Q4 2025—~$(85)M New
Interest Expense, netQ4 2025—~$(50)M New
Cepheid Respiratory RevenueFY 2025~$1.7B (maintained) ~$1.7B (maintained) Maintained
Cepheid Respiratory RevenueFY 2026—~$1.7B New 2026 view
DividendQ4 2025—$0.32 payable Oct 31, record Sept 26 Announced

Earnings Call Themes & Trends

TopicPrevious Mentions (Q1 & Q2 2025)Current Period (Q3 2025)Trend
Bioprocessing mix: consumables vs equipmentConsumables low double-digit; equipment soft; book-to-bill >1; high single-digit FY growth reaffirmed Consumables double-digit demand; equipment orders delayed, book-to-bill ~1; cautious equipment through year-end Improving consumables; equipment recovery deferred
China diagnostics policy (VBP/reimbursement)~$150M 2025 adverse impact; volumes consistent with expectations 2026 planning headwind $75–$100M; lapping Q4 2024 headwinds Headwind moderating into 2026
Cepheid respiratory & non-respiratoryNon-respiratory double-digit growth; respiratory tracking endemic ~$1.7B; 75–80% 4-in-1 mix Respiratory revenue pull-forward (~$125M); non-respiratory mid/high-teens growth; 2026 respiratory ~$1.7B Stable endemic respiratory; strong non-respiratory
Tariffs/MFN and equipment capexSeveral hundred million gross exposure offset; reshoring/investment timing uncertain Tone improving, tariffs more planable; MFN deals “workable”; expect brownfield first, greenfield later Policy clarity improving; capex cycle could extend
Productivity and cost actions$150M 2025 actions; margin framework anchored to EPS $175M in 2025 total; ~$250M net savings in 2026 (>100 bps margin expansion; ~$0.30 EPS tailwind) 2026 margin expansion visibility up
Capital allocationBias to M&A, opportunistic buybacks; flexibility ~$2B repurchases in Q3; new 35M authorization; bias to M&A with ROIC discipline Shareholder returns supported; M&A optionality

Management Commentary

  • “We’re investing in breakthrough innovation, enhancing our commercial execution, and driving meaningful productivity gains across our businesses.” — Rainer M. Blair .
  • “Adjusted diluted net earnings per common share of $1.89 were up approximately 10% year over year.” — Prepared remarks .
  • On equipment orders: “More confidence now… MFN negotiations… tariffs are starting to dial in… we’re seeing more activity…but we just haven’t seen those turn into orders yet.” — Rainer M. Blair .
  • On China localization: “By the end of the year, much of our diagnostic businesses, whether equipment or reagents, will be localized… we view this actually as advantageous.” — Rainer M. Blair .
  • On 2026: “Operating leverage and 2025 productivity initiatives to drive more than 100 bps of adjusted operating profit margin expansion… high single digit adjusted EPS growth before capital allocation.” — Prepared remarks .

Q&A Highlights

  • 2026 framework: Core growth 3–6% with >100 bps margin expansion; $250M net savings ($0.30 EPS tailwind); management anchors modeling to low end initially .
  • China diagnostics VBP: Planning $75–$100M headwind in 2026; lapping Q4 2024 impacts supports improvement .
  • Diagnostics upside: ~$125M respiratory pull-forward in Q3; Beckman outside China continues mid-single-digit growth momentum .
  • Bioprocessing equipment: Activity and quotations increasing (brownfield first), but orders not yet converting; cautious stance maintained .
  • Capital allocation: ~$2B buybacks in Q3; new authorization for up to 35M shares; continued bias to M&A with valuation discipline .

Estimates Context

  • Actuals vs S&P Global consensus: Adjusted EPS $1.89 beat $1.72; revenue $6.053B beat $6.000B. Street likely raises near-term EPS/FCF forecasts given magnitude and quality of beat (bioprocessing consumables, early respiratory).
    | Metric | Q3 2025 Consensus | Q3 2025 Actual | |--------|--------------------|----------------| | Primary EPS ($) | 1.72163* | 1.89 | | Revenue ($) | 5,997,749,920* | 6,053,000,000 |

Notes: Values retrieved from S&P Global.

Key Takeaways for Investors

  • Beat-and-raise quality: Broad-based beat with margin resilience and strong FCF; expect positive estimate revisions in EPS/FCF and increased confidence in 2026 margin expansion .
  • Watch respiratory seasonality: Q3 had ~$125M pull-forward; Q4/Q1 are peak — monitor mix and utilization to gauge sustainability of upside .
  • Bioprocessing upside optionality: Consumables remain robust; any policy clarity translating to equipment orders could add incremental growth and operating leverage .
  • China normalization: Diagnostics headwinds moderating into 2026; localization strategy offers defensiveness — track policy developments and local manufacturing milestones .
  • Capital returns: ~$2B repurchased and 35M authorization underpin per-share compounding; M&A bias maintained with disciplined ROIC lens .
  • Near-term trade: Stock likely reacts positively to beat and durable guidance; catalysts ahead include Q4 margin delivery (~27%) and confirmation of 2026 EPS/margin trajectory .
  • Medium-term thesis: Durable recurring revenue mix, leadership in bioprocessing/diagnostics, and DBS-driven productivity support sustained margin expansion and cash generation through cycles .

Citations:

  • 8-K and Q3 press release details:
  • Q3 earnings call transcript:
  • Q2 2025 press release and call:
  • Q1 2025 press release and call:
  • Dividend press release: